Filing Details

Accession Number:
0001209191-21-011486
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-17 18:45:54
Reporting Period:
2021-02-11
Accepted Time:
2021-02-17 18:45:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1503802 Karyopharm Therapeutics Inc. KPTI Pharmaceutical Preparations (2834) 263931704
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1588438 Sharon Shacham C/O Karyopharm Therapeutics Inc.
85 Wells Avenue
Newton MA 02459
President & Cso No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-02-11 6,642 $15.52 764,147 No 4 S Direct
Common Stock Acquisiton 2021-02-15 21,800 $0.00 785,947 No 4 M Direct
Common Stock Disposition 2021-02-11 6,601 $15.52 562,821 No 4 S Indirect By Spouse
Common Stock Acquisiton 2021-02-15 21,800 $0.00 584,621 No 4 M Indirect By Spouse
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Indirect By Spouse
No 4 M Indirect By Spouse
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2021-02-15 21,800 $0.00 21,800 $0.00
Common Stock Restricted Stock Units Disposition 2021-02-15 21,800 $0.00 21,800 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
43,600 No 4 M Direct
43,600 No 4 M Indirect
Footnotes
  1. This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
  2. The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.
  3. Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.
  4. This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.
  5. The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.
  6. On February 15, 2019, the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.
  7. On February 15, 2019, the spouse of the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.